Eli Lilly Profit Sinks On Patent Expirations

Eli Lilly said its second-quarter profit slid 39% as patent expirations for some of its bigger-selling drugs dragged down revenue and volume.

Topics:  eli lilly   profit   patent expirations   
BING NEWS:
  • Eli Lilly and Company (LLY)
    Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide) appears to spur the momentum after receiving FDA approval in November 2023. According to the FDA, limited supplies of Eli Lilly’s d Indian ...
    04/18/2024 - 5:00 am | View Link
  • Eli Lilly and Co Stock (NYSE:LLY), Quotes and News Summary
    Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025. Vandana ...
    04/17/2024 - 1:00 pm | View Link
  • Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
    Before market open, Eli Lilly announced that its molecule tirzepatide had achieved its primary endpoints in a set of phase 3 clinical trials. The studies aimed to judge its efficacy in treating ...
    04/17/2024 - 11:51 am | View Link
  • Eli Lilly and Company (LLY)
    Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected ...
    04/15/2024 - 1:10 am | View Link
  • Eli Lilly and Co
    We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
    04/14/2024 - 9:07 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News